Nasus Pharma is trading 11.34% down at $3.44, primarily as healthcare and broader markets come under pressure.

  • The decline reverses the September 8 conference-driven gain.
  • No new company-specific announcement explaining the September 9 decline was identified.
  • The latest company release concerns a September 14–16 H.C. Wainwright presentation; XLV is down 2.19%.